2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

José A. Joglar; Mina K. Chung; Anastasia L. Armbruster; Emelia J. Benjamin; Janice Y. Chyou; Edmond M. Cronin; Anita Deswal; Lee L. Eckhardt; Zachary D. Goldberger; Rakesh Gopinathannair; Bulent Gorenek; Paul L. Hess; Mark Hlatky; Gail Hogan; Chinwe Ibeh; Julia H. Indik; Kazuhiko Kido; Fred Kusumoto; Mark S. Link; Kathleen T. Linta; Gregory M. Marcus; Patrick M. McCarthy; Nimesh Patel; Kristen K. Patton; Marco V. Perez; Jonathan P. Piccini; Andrea M. Russo; Prashanthan Sanders; Megan M. Streur; Kevin L. Thomas; Sabrina Times; James E. Tisdale; Anne Marie Valente; David R. Van Wagoner

doi:10.1161/CIR.0000000000001193

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

José A. Joglar, Mina K. Chung, Anastasia L. Armbruster, Emelia J. Benjamin, Janice Y. Chyou, Edmond M. Cronin, Anita Deswal, Lee L. Eckhardt, Zachary D. Goldberger, Rakesh Gopinathannair, Bulent Gorenek, Paul L. Hess, Mark Hlatky, Gail Hogan, Chinwe Ibeh, Julia H. Indik, Kazuhiko Kido, Fred Kusumoto, Mark S. Link, Kathleen T. LintaGregory M. Marcus, Patrick M. McCarthy, Nimesh Patel, Kristen K. Patton, Marco V. Perez, Jonathan P. Piccini, Andrea M. Russo, Prashanthan Sanders, Megan M. Streur, Kevin L. Thomas, Sabrina Times, James E. Tisdale, Anne Marie Valente, David R. Van Wagoner

Research output: Contribution to journal › Review article › peer-review

332 Scopus citations

Abstract

AIM: The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

Original language	English (US)
Pages (from-to)	E1-E156
Journal	Circulation
Volume	149
Issue number	1
DOIs	https://doi.org/10.1161/CIR.0000000000001193
State	Published - Jan 2 2024

Keywords

AHA Scientific Statements
acute coronary syndrome
alcohol
anticoagulants
anticoagulation agents
antiplatelet agents
apixaban
atrial fibrillation
atrial flutter
cardioversion
catheter ablation
coronary artery disease
coronary heart disease
dabigatran
edoxaban
exercise
heart failure
hypertension
idarucizumab
left atrial appendage occlusion
myocardial infarction
obesity
percutaneous coronary intervention
pulmonary vein isolation
risk factors
rivaroxaban
sleep apnea
stents
stroke
surgical ablation
thromboembolism
warfarin

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1161/CIR.0000000000001193

Fingerprint

Dive into the research topics of '2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines'. Together they form a unique fingerprint.

Cite this

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., ... Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149(1), E1-E156. https://doi.org/10.1161/CIR.0000000000001193

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. / Joglar, José A.; Chung, Mina K.; Armbruster, Anastasia L. et al.
In: Circulation, Vol. 149, No. 1, 02.01.2024, p. E1-E156.

Research output: Contribution to journal › Review article › peer-review

Joglar, JA, Chung, MK, Armbruster, AL, Benjamin, EJ, Chyou, JY, Cronin, EM, Deswal, A, Eckhardt, LL, Goldberger, ZD, Gopinathannair, R, Gorenek, B, Hess, PL, Hlatky, M, Hogan, G, Ibeh, C, Indik, JH, Kido, K, Kusumoto, F, Link, MS, Linta, KT, Marcus, GM, McCarthy, PM, Patel, N, Patton, KK, Perez, MV, Piccini, JP, Russo, AM, Sanders, P, Streur, MM, Thomas, KL, Times, S, Tisdale, JE, Marie Valente, A & Van Wagoner, DR 2024, '2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines', Circulation, vol. 149, no. 1, pp. E1-E156. https://doi.org/10.1161/CIR.0000000000001193

@article{2a1e70a31e05454eb5527b3069fb27db,

title = "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines",

abstract = "AIM: The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.",

keywords = "AHA Scientific Statements, acute coronary syndrome, alcohol, anticoagulants, anticoagulation agents, antiplatelet agents, apixaban, atrial fibrillation, atrial flutter, cardioversion, catheter ablation, coronary artery disease, coronary heart disease, dabigatran, edoxaban, exercise, heart failure, hypertension, idarucizumab, left atrial appendage occlusion, myocardial infarction, obesity, percutaneous coronary intervention, pulmonary vein isolation, risk factors, rivaroxaban, sleep apnea, stents, stroke, surgical ablation, thromboembolism, warfarin",

author = "Joglar, {Jos{\'e} A.} and Chung, {Mina K.} and Armbruster, {Anastasia L.} and Benjamin, {Emelia J.} and Chyou, {Janice Y.} and Cronin, {Edmond M.} and Anita Deswal and Eckhardt, {Lee L.} and Goldberger, {Zachary D.} and Rakesh Gopinathannair and Bulent Gorenek and Hess, {Paul L.} and Mark Hlatky and Gail Hogan and Chinwe Ibeh and Indik, {Julia H.} and Kazuhiko Kido and Fred Kusumoto and Link, {Mark S.} and Linta, {Kathleen T.} and Marcus, {Gregory M.} and McCarthy, {Patrick M.} and Nimesh Patel and Patton, {Kristen K.} and Perez, {Marco V.} and Piccini, {Jonathan P.} and Russo, {Andrea M.} and Prashanthan Sanders and Streur, {Megan M.} and Thomas, {Kevin L.} and Sabrina Times and Tisdale, {James E.} and {Marie Valente}, Anne and {Van Wagoner}, {David R.}",

note = "Publisher Copyright: {\textcopyright} 2023 by the American College of Cardiology Foundation and the American Heart Association, Inc.",

year = "2024",

month = jan,

day = "2",

doi = "10.1161/CIR.0000000000001193",

language = "English (US)",

volume = "149",

pages = "E1--E156",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

T2 - A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

AU - Joglar, José A.

AU - Chung, Mina K.

AU - Armbruster, Anastasia L.

AU - Benjamin, Emelia J.

AU - Chyou, Janice Y.

AU - Cronin, Edmond M.

AU - Deswal, Anita

AU - Eckhardt, Lee L.

AU - Goldberger, Zachary D.

AU - Gopinathannair, Rakesh

AU - Gorenek, Bulent

AU - Hess, Paul L.

AU - Hlatky, Mark

AU - Hogan, Gail

AU - Ibeh, Chinwe

AU - Indik, Julia H.

AU - Kido, Kazuhiko

AU - Kusumoto, Fred

AU - Link, Mark S.

AU - Linta, Kathleen T.

AU - Marcus, Gregory M.

AU - McCarthy, Patrick M.

AU - Patel, Nimesh

AU - Patton, Kristen K.

AU - Perez, Marco V.

AU - Piccini, Jonathan P.

AU - Russo, Andrea M.

AU - Sanders, Prashanthan

AU - Streur, Megan M.

AU - Thomas, Kevin L.

AU - Times, Sabrina

AU - Tisdale, James E.

AU - Marie Valente, Anne

AU - Van Wagoner, David R.

PY - 2024/1/2

Y1 - 2024/1/2

N2 - AIM: The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

AB - AIM: The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation” provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

KW - AHA Scientific Statements

KW - acute coronary syndrome

KW - alcohol

KW - anticoagulants

KW - anticoagulation agents

KW - antiplatelet agents

KW - apixaban

KW - atrial fibrillation

KW - atrial flutter

KW - cardioversion

KW - catheter ablation

KW - coronary artery disease

KW - coronary heart disease

KW - dabigatran

KW - edoxaban

KW - exercise

KW - heart failure

KW - hypertension

KW - idarucizumab

KW - left atrial appendage occlusion

KW - myocardial infarction

KW - obesity

KW - percutaneous coronary intervention

KW - pulmonary vein isolation

KW - risk factors

KW - rivaroxaban

KW - sleep apnea

KW - stents

KW - stroke

KW - surgical ablation

KW - thromboembolism

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=85181069945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181069945&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000001193

DO - 10.1161/CIR.0000000000001193

M3 - Review article

C2 - 38033089

AN - SCOPUS:85181069945

SN - 0009-7322

VL - 149

SP - E1-E156

JO - Circulation

JF - Circulation

IS - 1

ER -

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this